TY  - GEN 
AU  - Pereyra-Rodríguez, José Juan
AU  - Herranz, Pedro
AU  - Ruiz-Villaverde, Ricardo
AU  - Elosua-González, Marta
AU  - Galán Gutiérrez, Manuel
AU  - Figueras-Nart, Ignasi
AU  - Miquel-Miquel, Javier
AU  - de la Cueba Dobao, Pablo
AU  - Serra-Baldrich, Esther
AU  - Munera-Campos, Monica
AU  - Melé-Ninot, Gemma
AU  - Expósito-Serrano, Vicente
AU  - Pérez, Bibiana
AU  - Serrano, Amalia
AU  - Ortiz de Frutos, Francisco Javier
AU  - Armario Hita, José Carlos
A4  - Cirugía
A4  - Medicina
PY  - 2023
SN  - 1365-2230
UR  - http://hdl.handle.net/10498/39535
AB  - Background Tralokinumab was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) and is the first selective interleukin (IL)-13 inhibitor that specifically neutralizes IL-13 with high affinity.
Objectives To determine the...
LA  - eng
PB  - Oxford University Press
KW  - atopic dermatitis
TI  - Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
DO  - 10.1093/CED/LLAD153
ER  -